Oncology Times - Ot Broadcasts From The Ipad Archives

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO. The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncology Times reporter Peter Goodwin about some of the key areas of progress covered by the meeting that she was most excited about.

A large international cohort study has found that women testing positive for the BRCA mutation who chose to breastfeed their babies after treatment for their breast cancer faced no additional risk to their cancer outcomes.    OncTimesTalk correspondent Peter Goodwin talked with Eva Blondeaux, MD, Medical Oncologist in the Epidemiology Unit at the IRCCS Ospedale Policlinico San Martino, Genoa, Italy, and the author of the study, after her presentation of the new data at the ESMO 2024 Congress.

Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024.    In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in the Division of Gynecologic Oncology at the European Institute of Oncology, Milan, Italy, after he reported his group’s findings. “Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial,” Peccatori noted.

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center, Singapore (with a special interest in all aspects of triple-negative breast cancer), shared the key areas of progress covered by the meeting.

HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated cancer incidence, reported at the 2024 ASCO Annual Meeting.  At the Chicago meeting, OncTimesTalk reporter Peter Goodwin met up with the lead author of the research, Jefferson DeKloe, BSc, from the Department of Otolaryngology at Thomas Jefferson University in Philadelphia.

Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression. The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.

Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting. OncTimesTalk reporter Peter Goodwin caught up with the lead study author Chiara Gottardi, MD, who specializes in head and neck cancer in the Department of Surgery, Oncology, and Gastroenterology in the Istituto Oncologico Veneto at the University of Padova in Italy.

A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of London were reported at a poster session of the 2024 ASCO Annual Meeting. Oncology Times correspondent Peter Goodwin attended the session and talked with the second author of the study, Weronika E. Borek PhD, a Bioinformatics Technical Lead at Kinomica Limited in London.

When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34 trial presented at the 2024 ASCO Annual Meeting. Oncology Times reporter Peter Goodwin met up in Chicago with the lead study author, Christian F. Singer MD, a gynecologist specializing in breast cancer at the Department of Obstetrics and Gynecology and the Comprehensive Cancer Center of the Medical University of Vienna, in Vienna, Austria.

Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncTimesTalk, correspondent Peter Goodwin spoke with Joseph A. Greer, PhD, lead author of the study and Co-Director of the Cancer Outcomes Research and Education Program at Massachusetts General Hospital and Harvard Medical School.

The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of Nantes was reported at the 2024 ASCO Annual Meeting. The researchers noted this surgical de-escalation allows significant reduction of serious post-operative morbidity After the session, Oncology Times correspondent Peter Goodwin learned about more study details from Jean-Marc Classe, MD, PhD, Professor of Surgery in the Department of Surgical Oncology in the Institut de Cancérologie de l'Ouest and Nantes University in Western France.

A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut melanoma, dabrafenib + trametinib). This research was reported from the ASCO 2024 Annual Meeting and highlighted the NADINA trial from the Netherlands. After his session at ASCO, the lead author of NADINA, Christian U. Blank, MD, PhD, from the Netherlands Cancer Institute and Antoni van Leeuwenhook Hospital, Amsterdam, the Netherlands, met up with Oncology Times reporter Peter Goodwin to discuss the findings.

Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital, the South Australian Health and Medical Research Institute, and the University of Adelaide in Australia, reported higher efficacy in terms of major molecular responses and lower toxicity with asciminib. After his talk in Chicago, he met up with Oncology Times reporter, Peter Goodwin.

Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the University of Bielefeld in Germany, spoke with Oncology Times reporter Peter Goodwin about his group’s comparison of neoadjuvant therapy using the CROSS (41.4 Gy plus carboplatin/paclitaxel) regimen followed by surgery, with the use of an alternative protocol: perioperative FLOT (5-FU/ leucovorin/oxaliplatin/docetaxel) and surgery, in which chemotherapy is given both before and after curative surgery.

Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy.  After announcing the results at the 2024 ASCO Annual Meeting, first author Giuseppe Curigliano, MD, PhD, Director of Early Drug Development for the Innovative Therapies Division of the European Institute of Oncology, discussed the findings with Oncology Times correspondent Peter Goodwin

New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progression after definitive chemoradiotherapy. In Chicago, Oncology Times reporter Peter Goodwin met up with lead author of the LAURA study, Suresh S. Ramalingam MD, Executive Director of the Winship Cancer Institute at Emory University School of Medicine in Atlanta.

Facebook Twitter Linkedin Reddit Word File Edit Insert View Format Table Tools Formats pWords: 89 Sample HTML Undo New page indentation compress encoding option ico option2 option3 option4 option5 option6 option7 option8Clean When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study reported in the Plenary Session at the 2024 ASCO Annual Meeting in Chicago. Peter Goodwin was there for Oncology Times, where he talked with the lead author of the new research, David Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute in Nashville, TN. Characters: 657 × Paste or compose your doc in the editor and switch to HTML view to get the code! Word Doc to HTML Online Converter Word Docum

An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the conference, Oncology Times reporter Peter Goodwin met up with Peter Borchmann, MD, PhD, the lead author of the new research and Chair of the German Hodgkin Study Group at the University Hospital of Cologne in Germany.

The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group’s early findings of AZD1390, an inhibitor of ataxia telangiectasia mutated (ATM) kinase studied in 115 patients with recurrent or newly diagnosed glioblastoma, first author Jonathan T. Yang MD, PhD, previously from the Memorial Sloan Kettering Cancer Center and now at UW Medicine, stepped into the Oncology Times studio at the AACR conference to tell OncTimesTalk’s reporter Peter Goodwin about the safety of this new agent and the clinical value it could bring in glioblastoma.

A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR Annual Meeting. The randomized study, led by the researchers at the Moffitt Cancer Center, looked at a combination of the mRNA-based active cancer vaccine BI1361849 combined with the anti-PD-L1 checkpoint inhibitor durvalumab with or without the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibitor tremelimumab immunotherapy. After announcing the findings at the AACR, presenting author Dung-Tsa Chen, PhD, Senior Member in the Department of Biostatistics & Informatics, Special Clinical Trial Design, and Data Analysis at the Moffitt Cancer Center, called in to discuss the new data with OncTimesTalk correspondent Peter Goodwin.